β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer

Programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) checkpoint blocking antibodies have been shown to be a powerful immune checkpoint blockade (ICB) therapy for patients with cancer. However, patients quickly develop resistance to immunotherapy. β-glucan, an immune adjuvant, has been found to stimulate in...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Mengjie Wang, Yu Bai, Jiaxin Pei, Dongqing Li, Xiaolin Pu, Wenyu Zhu, Lei Xia, Chunjian Qi, Hua Jiang, Yongling Ning
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2022-04-01
Saila:	Frontiers in Pharmacology
Gaiak:	β-Glucan PD-1 PD-L1 immune checkpoint blockade therapy resistance
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fphar.2022.887457/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!